Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates

Beek, Ermond R. van; Cohen, Louis; Leroy, Ingrid; Ebetino, Frank H.; Löwik, Clemens W.G.M.; Papapoulos, Socrates E.

doi:10.1016/j.bone.2003.07.007

Cited by 172 publications

(111 citation statements)

References 26 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…BPs act by inhibiting the osteoclastic resorption of bone tissue (Colucci et al 1998;Van Beek et al 2003), they bind strongly to HA crystals and are retained for a long time in bone, being excreted unmetabolized in urine (Papapoulos 2006;Panzavolta et al 2009). Chemically, BPs are analogous to pyrophosphates, which are natural modulators of bone metabolism (Nancollas et al 2006;Nieto et al 2008).…”

Section: Bisphosphonatesmentioning

confidence: 99%

Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds

Mouriño

Boccaccını

2009

J. R. Soc. Interface.

463

294

View full text Add to dashboard Cite

This paper provides an extensive overview of published studies on the development and applications of three-dimensional bone tissue engineering (TE) scaffolds with potential capability for the controlled delivery of therapeutic drugs. Typical drugs considered include gentamicin and other antibiotics generally used to combat osteomyelitis, as well as anti-inflammatory drugs and bisphosphonates, but delivery of growth factors is not covered in this review. In each case reviewed, special attention has been given to the technology used for controlling the release of the loaded drugs. The possibility of designing multifunctional three-dimensional bone TE scaffolds for the emerging field of bone TE therapeutics is discussed. A detailed summary of drugs included in three-dimensional scaffolds and the several approaches developed to combine bioceramics with various polymeric biomaterials in composites for drug-delivery systems is included. The main results presented in the literature are discussed and the remaining challenges in the field are summarized with suggestions for future research directions.

show abstract

Section: Bisphosphonatesmentioning

confidence: 99%

Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds

Mouriño

Boccaccını

2009

J. R. Soc. Interface.

463

294

View full text Add to dashboard Cite

show abstract

“…The bisphosphonate compounds are analogs of inorganic pyrophosphate in which the oxygen atom has been replaced with a carbon atom (22)(23)(24)(25). The phosphate-carbon-phosphate group accounts for the unique high-affinity binding property of these compounds to the hydroxyapatite component of the bone matrix and provides the unique pharmacologic advantage of generating a high local concentration of the drug on the bone surface, where these agents can act directly to interfere with osteoclast-mediated bone resorption.…”

mentioning

confidence: 99%

Bisphosphonates: Environmental protection for the joint?

Goldring¹,

Gravallese²

2004

Arthritis & Rheumatism

View full text Add to dashboard Cite

“…The non-nitrogenous bisphosphonates(disphosphonates) are metabolised in the cell to compounds that replace the terminal pyrophosphate moiety of ATP, forming a nonfunctional molecule that competes with adenosine triphosphate (ATP) in the cellular energy metabolism. The osteoclast initiates apoptosis and dies, leading to an overall decrease in the breakdown of bone (5,6).…”

Section: Classificationmentioning

confidence: 99%